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Abstract
Facial  transplantation offers an alternative approach towards restoring gross facial
disfigurement. Since its advent in 2005, the surgical principles have become continually
refined depending on the nature of the injury and anatomical requirements posed by the
recipients. Owing to the complex nature of the procedure, it bears a number of different
risks. These have included graft rejection from alloimmune responses, complications from
the effects of immunosuppression and risk of mortality; in addition, there is an inherent
predisposition for the development of psychological complications. This chapter outlines
the stepwise process of conducting a facial transplantation with emphasis on key surgical
principles. It also provides details with case examples of how to minimize complica‐
tions associated with the procedure.
Keywords: risks, facial transplant, surgical principles, complications, composite tissue
allograft
1. Introduction
Facial transplantation has revolutionized complex forms of reconstruction where convention‐
al procedures have produced suboptimum results [1–3]. Originally conducted in 2005 [4], it has
redefined the technical boundaries of plastic surgery with many more having been conducted
globally. However, performing a facial composite tissue allotransplantation (CTA) poses a
significant number of challenges, which were anticipated early on [5]. Psychological complica‐
tions can be profound [1] and therefore pre-operative mental assessment is vital [6, 7] to ensure
engagement with the long-term multidisciplinary team therapy. Failure to do so has resulted
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in mortality in one case due to lack of compliance with the immunosuppressive regime [1]. Acute
rejection episodes have affected all allograft recipients [1, 8, 9] with one patient having had
sustained a chronic rejection of the CTA [10]. The adverse effects of immunosuppression have
been depicted within the literature, most notably an increased predisposition towards acquir‐
ing infections, which have affected a significant proportion of recipients [1]. Functional outcomes
have so far exceeded expectations with all patients having demonstrated good motor and sensory
development [4, 8, 11]. Motor recovery has, however, been slightly lagging in comparison to
neurosensory restoration [1, 3, 12]. There have been three post-operative mortalities associat‐
ed with facial CTAs so far [1]. Miscellaneous complications including renal insufficiency, blood
loss and neoplasia development have been encountered too [1]. This chapter aims to draw focus
towards the management of risks in facial transplantation and offers an insight into revising
existing protocols. In addition, an overview concerning the principles of surgical approach in
performing the procedure is addressed.
1.1. Ethical aspects
Ethical debates raised in the case of facial transplantation emphasize on the significance of the
risks associated with the procedure taking into account that is not considered life saving but
life changing [13]. In addition, the face unlike other forms of organ transplantation is unique
to each person and represents one’s individuality; the ethical dilemma, therefore, of a transfer
of identity is an issue debated by many. So far, however, many of these concerns have been
answered with the promising results of transplanted CTAs. No psychological complications
of an identity crisis have yet been reported in the literature. All individuals have shown great
functional improvement thus justifying the importance of the procedure [1]. Despite this, the
associated risks have still meant that clinical and public opinion remains divided regarding
the ethics of the surgery.
1.2. Malformations
Severe facial malformations not amenable to routine reconstructive methods serve as ideal
indications for facial transplantation. So far, reports have included injuries sustained from
shot-gun injuries, animal attacks, carcinomas and burns [1]. Such is often the severity of these
defects that it would require countless surgeries over many years and still this would only be
expected to produce suboptimum results. The unique ability of facial composite tissue
allografts to correct gross disfigurement successfully in a single procedure has made it an ideal
option.
1.3. Donor and recipient matching
It is important to identify the correct donor and recipient match for the surgery to be successful.
Age, race, skin colour and blood type are some of the important considerations to take into
account. This will lead to a more aesthetic outcome in keeping with the rest of the recipient’s
physical makeup. Also, a closer anatomical match will allow for an easier apposition of the
procured CTA on to the donor.
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1.4. The surgical experience
1.4.1. Pre-operative workup
1.4.1.1. Imaging
Prior to transplanting a facial CTA, thorough pre-operative imaging is necessary in order to
outline the anatomical characteristics of the recipient [14]. This will help to guide the surgery
in accordance with an individualized protocol. Computerized tomography (CT) scanning of
the head and neck will delineate the bony structure of the recipient and can produce accurate
specifications of the disfigurement. Three-dimensional (3D) reconstruction of the CT images
can then help guide osteosynthesis of the recipient’s bony framework to allow for finer
anatomical apposition with the donor CTA.
Detailed venous and arterial assessment of the recipient has so far been best achieved by CT
angiography. This has allowed for identifying inflow and outflow vessels aided by spatial
resolution. It has shown to be more superior than magnetic resonance imaging (MRI) angiog‐
raphy as it has a greater potential to detect smaller vessels and with less artefacts. CT angio‐
grams have therefore been identified as the first-line modality for delineating the recipient’s
vascular makeup [15] (Figure 1).
Figure 1. CT angiogram (left) demonstrating fine anatomical outline of internal maxillary, lingual and superior thyroid
arteries in contrast to MR angiography which offers less resolution (right). Image reproduced from Shigeyoshi et al.
[15].
1.4.1.2. Nerve function
Sensory-motor status of the recipient is assessed through electromyographic (EMG) studies.
This helps evaluate the current neurological status and guides microscopic anastomosis of the
nerves. This form of mapping is essential towards the success of the surgery. In addition, post-
operative EMG results can be later compared to assess recovery and guide rehabilitation.
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1.4.1.3. Oropharyngeal assessment
This is important so as to identify any underlying dental abscesses or periodontal disease
which may require treatment prior to surgery. Such conditions can reduce the rate of post-
operative recovery as it leads to immunomodulation, which could manifest in acute graft
rejection.
1.4.1.4. Screening for carcinomas
The detection of underlying carcinomas in recipients is important as it can result in significant
complications. In addition, it may also lead to reconsideration as to whether the recipient is at
all a suitable candidate for the procedure. Immunocompromised states such as carcinomas
would predispose individuals to a greater risk of opportunistic infections; also, immunomo‐
dulation due to reducing the immunosuppression regime can result in acute graft rejection.
Recipients need to undergo screening for any oropharyngeal carcinomas, women over the age
of 40 should be up to date with mammography and all patients above the age of 40 should
undergo upper as well as lower endoscopy to detect underlying undiagnosed carcinomas [14].
The literature has depicted the severity of carcinomatous conditions on recipients of facial
transplantation. A recurrent squamous cell carcinoma in one individual resulted in a mortality
[3], which ultimately undermined the indication for performing the procedure in the first
instance.
1.4.1.5. Anaesthetic assessment
The anaesthetic workup for performing facial CTAs just like other forms of solid organ
transplantation begins with the routine evaluation of cardiovascular and respiratory status.
This is aided by transthoracic echo and lung function tests, respectively. These tests although
routinely conducted in those aged greater than 50 years should also be considered for younger
patients if they possess risk factors for cardiopulmonary disease. Routine bloods to identify
pre-existing coagulopathies or biochemical deficiencies are an important step in any pre-
surgical workup [14].
An essential aspect of the anaesthetic assessment is delineating the airway anatomy in
recipients of facial CTAs and this can be a complex process due to the severe nature of the
injuries sustained. Often, there is gross disfigurement of the normal anatomy not only from
the physical injury itself but also from numerous failed reconstructive attempts, which poses
greater challenges in airway management. Pre-planning can be aided by reviewing the
relevant imaging including both CT and MRI scans to obtain greater detail. Intraoperative
management often involves the use of a tracheostomy; this not only avoids the difficulties in
obtaining a definite airway as is a problem in recipients of facial CTAs but also keeps the facial-
operating field clear for the surgeon.
Owing to the complexity of facial transplantation surgery as well as the haemorrhagic risk,
obtaining adequate vascular access is an important element that requires careful consideration.
Femoral lines not only provide a good mode of intraoperative monitoring but also abide in
keeping the surgical field clear [16]. This is an important anatomical consideration.
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1.4.1.6. Donor prosthesis
Procurement of the facial CTA is known to create significant disfigurement at the donor site.
In abiding to transplantation principles, which have previously stated that a sufficient aesthetic
appearance should be obtained post organ retrieval [17], it is therefore important to take this
factor into account. The process of producing a suitable prosthesis can be initiated pre-
operatively whilst the donor is in ITU, an alginate material can be employed to obtain an
impression of the donor’s face, which is converted to a plaster of Paris (POP) cast in the
laboratory. After this stage, a silicone putty material can be poured over this cast and a facial
plaster of Paris structure can be obtained. Adhesive dental carding wax can be applied to
reproduce the dimensions of skin and subcutaneous tissues over the POP prosthesis. A silicone
elastomer can be finally mixed with it in the last stage. Artificial hair and eyebrows can be
fabricated on to the prosthesis [18]. This can then be used post-operatively to cover the donor’s
facial defect.
1.4.2. Intraoperative period
The intraoperative period involves two surgical teams working simultaneously with one
group involved in the procurement of the donor CTA and the other concerned with the
preparation of the recipient to undergo implantation of the donor allograft.
1.4.2.1. Retrieval of the donor allograft
A major aim of transplant teams in the procurement of facial CTAs is to limit the ischaemia
time. Heart-beating donors offer a greater period in which to arrange for the retrieval of the
allograft and transfer it to the recipient [19]. The process of procurement begins after the
anaesthetic teams perform a tracheostomy of the donor.
The next stage involves marking the boundaries of the CTA to be dissected as displayed in
Figure 2:
Figure 2. Marking the boundaries for dissection on the donor. Note the extension of margins into the neck to provide
additional tissue as part of the allograft. The extra section allows for adjustments to be conducted during transplanta‐
tion on to the recipient as well as providing tissue for obtaining grafts to aid reconstructing residual defects.
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A silastic sheet can be employed as a template to delineate the margins that need to be incised.
This template is produced based on the specifications of the defect of the recipient and is then
placed on to the donor to guide the surgeons of the retrieval margins. Models produced by 3D
printers specifying the exact dimensions of the recipient’s defect can help guide the depth of
dissection on the donor. Depending on the structural and functional needs of the recipient,
discretion is advocated as to what facial component and nerve structure is required for
preservation.
After the initial incisions, the facial flap is elevated and the major vessels are identified
including the facial arteries and external jugular veins. Vascular loops can be employed in
labelling them. The facial artery is often preserved and dissection involves separating it from
its point of attachment with the external carotid artery. A bi-coronal incision is often employed
in removing the donor CTA; this is extended along the subperiosteum up towards the level of
the orbits. It is then extended laterally and may include the ears if they are needed; however,
if not, then a rhytidectomy incision can be employed. A deep plane is usually required for the
incision so that when undermining of the facial CTA is being performed, skin, soft tissues and
muscles can all be obtained. Nerves that require transection can be tested by stimulators to
assess their functional status before deciding whether to transfer them with the facial CTA [14,
19, 20] (Figure 3).
Figure 3. Elevation of flap after creating a bi-coronal incision. Arrow heads depicting incision trajectory.
In procurement of the craniofacial skeleton, superior osteotomies can be employed just above
the lateral canthi bilaterally [20, 21]. These can be advanced forward to include variable sections
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of the maxilla, zygoma and orbits depending on the anatomical requirements of the recipient.
These structures can be elevated by pressure underneath after having been transected at the
appropriate points. Haemostatic control is important when the facial CTA is being removed
from the donor. The facial arteries and veins are clamped bilaterally and transected. The defect
produced within the donor can be covered up with a silicone prosthesis as aforementioned.
Figure 4. (a) Example of a sub-SMAS (subsuperficial muscular aponeurotic system) facial allograft in a cadaveric mod‐
el after procurement containing skin and soft tissues. (b) Example of a subperiosteal Le Fort III graft. Image repro‐
duced from Baccarani et al. [21].
The type of flap needed to be harvested and the structures required for preservation is
dependent on the anatomical dimensions of the defect to be repaired. If only soft tissues are
required, then a sub-SMAS (subsuperficial muscular aponeurotic system) graft can be
obtained, which involves dissection from the vertex down towards the subplatysmal plane. If
bony structures are necessary for procurement, then a subperiosteal Le Fort III harvest can be
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conducted. This involves dissection down from the vertex towards the subperiosteal plane
instead followed by a Le Fort III osteotomy to obtain sections of the facial skeleton in addition
to soft tissues (Figure 4).
1.4.2.2. Preparation of the recipient
Often when bony reconstruction is required it commences with osteosynthesis of the donor’s
facial bones most notably the maxilla, zygomatic arch, orbital rim and mandible depending
on the nature of the injury. The dimensions are surgically modified to match those of the donor
allograft so as to allow for a more natural apposition. This in addition to offering a more
aesthetic result bares an important physiological benefit because closer anatomical alignment
of the sinuses reduces the risk of sinusitis from poor aeration. Conventional wires, plates and
screws aid this phase of the reconstructive process. Initially, a temporary osteosynthetic
method may be employed so as to proceed much earlier to microvascular anastomosis, which
would reduce the duration of ischaemic insult to the facial CTA. When the risk of ischaemia
has been alleviated, the completion of bony realignment can be carried through.
The next phase of the facial transplantation procedure will include coaptation of both motor
and sensory nerves. This technique involves meticulous microsurgical reattachment of the
nerves to enable functionalisation of the donor allograft. If recipient nerves have been damaged
by previous deformities, then they can be reconstructed through the aid of donor cable grafts
for which a number of host nerves can be employed. These include the facial, infraorbital,
supraorbital, inferior alveolar nerves and mental nerves. A mastoidectomy can often be
employed to obtain additional facial nerve length within the host. This enables for extrusion
outside of the bony facial canal and allows for easier attachment during cable grafting. A
similar method in the form of an orbital osteotomy can be conducted to provide the release of
the infraorbital nerve. This technique will allow for a more tension-free attachment. Points of
skin attachment of the facial CTA to that of the recipient should ideally be performed along
natural lines of cleavage such as the nasolabial folds. This will allow for a more tension-free
closure offering a better aesthetic outcome [22, 23]. The original surgical technique in full facial
CTAs involved bilateral inclusion of superficial temporal and facial arteries often with the
parotid gland, which gave poor aesthetic outcomes. This method became revised in 2012 when
it was shown that the inclusion of the facial arteries alone was sufficient to produce desirable
outcomes thus simplifying the surgery [23]. In addition, the exclusion of the parotids allowed
for more distal nerve coaptation. Recently, there has been an increase in revision surgeries post
transplantation [24]. Results have been favourable [1, 23, 24] without major complications, thus
offering an additional option towards enhancing both aesthetic and functional outcomes of
the CTA.
1.4.3. Revision surgeries
Secondary procedures post transplantation can be employed in order to revise residual
functional and aesthetic defects. These have included bony realignment, soft-tissue resuspen‐
sion, dermabrasion, skin grafting and fat injection [1].
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Dermabrasion is a method of surgical planning that can be conducted under local anaesthetic.
The epidermis is abraded to a variable extent; however, this certainly carries the risk of
bleeding as well as acquiring infections. Refined techniques including CO2 laser resurfacing
as well as electrobrasion have become more renowned and carry less risks [25]. These can help
eliminate scars post transplantation as well as remove abnormal pigmentation of the CTA
giving enhanced skin texture and appearance.
Both skin grafts and fat injections can be employed to correct residual anatomical defects
within the hybrid facial structure. Skin grafts, however, expose the patient to the added risk
of anaesthesia as well as post-surgical infections which may provide a challenge to eliminate
especially in the presence of immunosuppressant medications.
Bony realignment post-transplantation is one of the more invasive revision procedures and
carries a greater risk of complications since it involves the resection of the facial CTA to obtain
access to the craniofacial skeleton. For this reason, effective pre-operative surgical planning is
vital to avoid this clinical scenario.
1.4.4. Pre- and post-operative outcomes
In the subsequent text, we provide example cases of pre- and post-operative outcomes
(Figure 5).
Figure 5. Pre- and post-operative outcomes for facial transplantation, adapted from Khalifian et al. [1].
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1.4.5. Post-operative management
1.4.5.1. Rehabilitation
The post-operative period is an essential time when effective multidisciplinary team rehabil‐
itation can help maximize function of the allograft. This process includes a host of different
teams constituted by speech and language therapists, occupational as well as physical
therapists. In addition, engagement with psychological teams and dietary teams is crucial too.
The patient needs to cognitively recognize the new facial structures he/she has been trans‐
planted with. Research has shown that early and extensive rehabilitation of facial musculature
is important in aiding cerebral recognition [26]. The recipient needs to learn how to make the
newly acquired musculature functional. Exercises with physical therapists can help achieve
this process by practising different facial expressions. Speech therapy is essential in order for
the patient to not only be able to regain full vocal ability but also be able to safely swallow.
It is important to assess nerve innervation post transplantation to not only establish the
technical success of the microsurgical reattachment but also ensure that rehabilitation will be
a success. Nerve function is best assessed with EMG studies.
Occupational therapists can help ensure that patients are able to cope with activities of daily
living at home prior to discharge and clinical psychologists are able to address any concerns
regarding the development of identity issues. Ultimately, the post-operative period involves
a strong multidisciplinary approach to allow for the functional success of the transplanted
CTA.
1.5. Management of risks
Minimizing risk in the case of facial transplantation requires effective pre-operative planning
as well as robust measures to tackle any post-operative complications. Over the years as the
transposition of facial CTAs has increased, important lessons have been learnt about avoiding
adversities. This has helped to continually refine protocols to minimize risks.
1.5.1. Graft rejection
1.5.1.1. Acute rejection
Graft rejection is a universal drawback to all forms of transplantation [27, 28] and was
considered a definite risk to recipients of facial allografts in 2006 [5]. Despite advancements in
immunosuppressant therapy, acute graft rejection has been evidenced in the literature [29,
30]. All current documented cases of facial transplants have sustained episodes of acute
rejection [8, 9]. However, they have been well controlled with changes in immunosuppressive
therapy preventing graft loss. An incidence of 50% [31] (in reference to hand transplants) was
predicted initially [5]; however, until present 100% of reported cases in the literature have
succumbed to modes of acute rejection [1, 8, 9].
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Facial transplant  Acute rejection – Time Period  Treatment  Outcome 
November, 2005
Amiens, France,
performed by
Devauchelle and
Dubernard32 
Acute rejection episode
sustained on post op day 24 
Prednisolone was used at a higher dose
from 25 to 60 mg/kg daily. Tacrolimus and
clobetazol ointments were employed. The
dose of mycophenolate mofetil was
increased 
Normal outcome 
April, 2006 Xi’an,
China Guo33 
Episodes of acute graft rejections
occurred in months 3, 5, and 17
after transplantation 
Tacrolimus dose adjustment and
methylprednisone therapy for 5 days. The
steroid regime was tapered subsequently
by a gradual reduction of the dose 
Normal outcome 
January, 2007 Paris,
France Lantieri1 
Two episodes of rejection
occurred on days 28 and 64. 
Prednisolone was increased to 60mg for 3
days along with 3 daily 500mg IV boluses
which were administered 
Resolution of the
rejection episode
clinically however
biopsies still
demonstrated
evidence of graft
rejection 
December, 2008
Cleveland, OH, USA
Siemionow1 
On day 47, biopsy revealed Banff
III/IV). rejection of the graft 
A single dose of IV corticosteroids  Normal outcome
shown by negative
biopsy 
March, 2009 Paris,
France Lantieri1, 34 
Biopsies showed a grade 1 acute
T cell mediated acute rejection 
Intravenous methyrlprednisolone for 3
consecutive days with ATG therapy 
Normal resolution 
April, 2009 Boston,
MA, USA
Pomahac35 
On post-op day 17, the patient
developed facial redness. Flap
biopsies showed a grade 1
rejection 
A methylprednisolone bolus was given.
And MMF was switched to mycophenolic
acid
At day 74 and 107, topical treatment
included clobetazol cream. This was given
between days 27-35 and 37-45 as well.
Tacrolimus cream was used on day
107-113.
Metronidazole cream was given on day
115 for rosacea infection 
Normal outcome
(An undiagnosed
case of rosacea
infection went
undetected in the
donor allograft
tissue which
delayed
treatment) 
August, 2009 Paris,
France Lantieri2 
One episode at day 5 of acute
rejection 
Intravenous methylprednisolone doses on
3 consecutive days as well as
administration of ATG 
Normal outcome 
August, 2009
Valencia, Spain36 
Two acute
rejection episodes occurred on
postoperative days 14 and 350
(Banff l, grade III) 
Methylprednisolone 500 mg/24 hrs for 5
days. 
Normal outcome 
November, 2009
Amiens, France
Devauchelle 9 
5 episodes of acute rejection on
day 41, day 103, month 6, 16 and
18th 
Antithymocyte globulin, tacrolimus and
prednisolone were all employed 
Normal outcome 
Table 1. Example cases of acute rejection episodes with treatments and outcomes.
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Analysing all current documented cases of facial transplants, they have all sustained episodes
of acute rejection [1], which contrasts to the initial predicted incidence of 50% based on hand
transplants [5]. However, all episodes have been well controlled with changes in immuno‐
suppressive therapy therefore preventing graft loss in the acute stage. Table 1 demonstrates
some cases where the timelines of acute rejection episodes have been reported along with the
treatment method and outcome. Currently, no graft loss from acute rejection has been reported
[1, 8, 9]; however, detailed explanation of the nature of all acute rejections in the literature is
still pending.
Although the majority of acute rejection episodes have been well controlled, greater clinical
research is needed to reduce the incidence when performing facial transplantation as it hinders
post-operative recovery. For now, strict early recognition protocols should be adapted to allow
for timely detection and treatment.
1.5.1.2. Chronic rejection
Chronic graft rejection can result in progressive fibrosis of skin with ultimate graft failure [37].
So far, there has been one case reported within the literature. This occurred subsequent to the
minimization of immunosuppressive therapy due to an Epstein-Barr virus (EBV)-positive B-
cell lymphoma [10]. The chronic rejection ultimately compromised graft function with
evidence of reduced mouth opening [10]. Such a rejection event can be avoided if better donor
and recipient matching for EBV is conducted. Also, strict management protocols of acute
rejection episodes should be adapted for the prevention of any potential progression towards
a chronic mode of rejection.
1.5.2. Infections
Immunosuppression causes an increased predisposition to acquiring infections and Butler had
collectively referred to all the adverse effects that could potentially surface from immunosup‐
pressive agents [5]. Infective complications have affected 11 patients of transplanted allografts
so far [1, 38]. Lack of pre-transplantation detection of cytomegalovirus has led to six recipients
acquiring the infection [2, 38]. Bacterial infection has been reported in eight cases with five
patients developing sepsis [3]. Leukopenia has also been experienced amongst two recipients
who had their medication regime altered to lower doses [39, 40]. With respect to the high
proportions of infections developing in the recipients of facial allografts, it is fair to say that
we should employ better pre-op screening techniques to reduce the incidence of transmission.
Certainly, viral screening of the allografts could have prevented cytomegalovirus transmission
and reduced the incidence of infections encountered. Such a protocol should be considered for
future transplantations. Also, early recognition is key as in one case an underlying Candida
infection was misdiagnosed [3] as an acute rejection episode and this can lead to a delay in
treatment. Maintenance immunosuppression certainly poses significant risks for facial CTAs
and this like other forms of allotransplantation is dependent on the success of tolerance regimes
to provide better functional outcomes. So far, clinical trials have included Tregs, which are
regulatory T cells and are believed will be able to induce tolerance enabling graft survival.
Recent evidence also points to focusing research on the role of effector cells such as T cells as
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well as B cells as they are believed to possess key roles in regulating inflammatory responses
[41, 42]. Tolerance would allow for better outcomes in facial CTAs as it would eliminate the
need for long-term immunosuppression.
1.5.3. Mortality
There have so far been three reported mortalities in the case of facial transplantation [1]. The
Chinese case failed in complying with long-term immunosuppressive therapy ultimately
resulting in multi-organ failure [1]. A second case who received bilateral simultaneous below
elbow upper limb transplants in conjunction with a facial transplant sustained a cardiac arrest
in the post-operative period whilst in ITU after being treated for septic shock and pneumonia
[2, 43]. Another patient who also underwent simultaneous hand and facial transplantation
sustained upper limb ischaemia subsequent to septic shock and the hand transplants were
removed with salvage of the facial allograft [2]. This indicates that perhaps concomitant limb
and facial transplantation should not be conducted due to increased risk of post-operative
complications. The third patient mortality stemmed from a squamous carcinoma development
of the tongue in a human immunodeficiency virus (HIV)-positive patient [36, 43]. This
indicates that patients with severe co-morbidities should not be considered as recipients
particularly in those with immunocompromised states.
1.5.4. Functional outcome
Results concerning functional improvement have been positive with increased ability to
perform basic facial functions [2, 4, 8]. Regression of normal motor function has been encour‐
aging although slightly slower than sensory restoration [2, 12]. Despite this, the first case in
France regaining the ability to eat and drink after 1 week [10] has displayed great promise.
Equally, results have been paralleled globally with a case in Spain regaining full swallowing
ability at 16 months [36, 44]. This demonstrates that motor function restoration can be just as
swift as that of sensory. Gross return of lip motion has been reported too at 3 months [3].
Pomahac has reported restoration of olfaction as early as the third post-operative day and a
return to facial sensation at 3–4 months time for the three cases he has addressed [3]. Chronic
pain induced by skin contractures has also been obliterated and offered an additional mode
of function improvement [1]. Fischer et al. have demonstrated significant improvement in
numerous facial functions including speaking, breathing, eating, smelling, improved facial
expression as well as sensation in the vicinity of a single study [45]. They report that between
20 days and 1 year, all patients were capable of oral food intake with removal of all feeding
tubes, after 9 months all patients at their centre had regained intelligible speech, which
correlated with other studies within the literature, olfactory sensation was recovered in 100%
of cases where it was previously impaired, significant improvements in breathing were
reported too, facial expression was, however, only reported to increase in 76% of reported
cases. A unique finding that has been deduced from facial transplants is the efficiency of
sensory nerve reinnervation even when they have not been directly opposed in terms of
microvascular restoration. Restoration of sensory function has still been very good [2, 11]. This,
however, has not been the case in terms of motor function where poor anastomotic recon‐
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struction has been reflected by lack of motor improvement [45]. Therefore, a standardized level
of microvascular reconstruction should be aimed for so as to obtain both satisfactory motor
and sensory reinnervation. Early rehabilitation of facial musculature is important in facilitating
a normal outcome and therefore a multidisciplinary approach including speech and language
therapy is important as it aids cerebral recognition of newly transplanted facial musculature
[4].
1.5.5. Psychological risks
Psychiatric evaluation of patients for the receipt of donor facial CTAs is essential in order to
minimize risk. Patients who are considered for selection must acknowledge the pros and cons
of the procedure, be highly motivated as well as appreciate the importance of engagement
with long-term multidisciplinary team therapy [32]. Some of the contraindications include
active psychotic disorders, severe personality disorders as well as previous suicide attempts
[32]. Viewing an altered facial structure can induce emotional stress as an individual fails to
recognize his/her own identity [28]. However, until now there has been no documented
psychological complications due to altered identity with recipients having had accepted their
new appearance [5, 19, 25]. Recipients have also been shown to not possess donor resemblance
[29, 30] as was initially predicted by Butler [16], thus nullifying these perceived risks. Results
overall have shown positive outcomes with reports of reduced depression and a sense of
greater social integration amongst patients treated with the facial CTAs [14].
Despite thorough psychological assessment for the selection of patients, there has been one
case in China where lack of motivation in compliance with long-term immunosuppressive
therapy has contributed to a mortality [14]. This emphasizes the importance of maintaining a
robust pre-operative psychological workup as well as the need for post-operative psycholog‐
ical follow-up.
It is important to appreciate maintaining a quantitative method of assessing psychological
changes. Coffman et al. have emphasized the use of various psychological scales in order to
achieve this [46]. They followed outcomes for up to 3 years in a recipient of a facial CTA and
quantified their findings. Scaling systems were used every 3 months for the first 2 years and
then every 6 months. The Psychosocial Adjustment to Illness Scale (PAIS-SR) scoring system
was employed in order to assess social reintegration and psychological distress. The patient’s
Perception of Teasing FACES scores decreased from 25 to 9 at the last follow-up. PASTAS-
State (Physical Appearance State and Trait Anxiety Scale: State) was utilized in order to
evaluate the patient’s mental state in accordance to their body and facial image. Overall, it
showed an improvement during the course of the 3 years. Other scales that were used included
the Beck Depression Inventory, which decreased from 16 to 6 by 3 months, and the PAIN
thermometer, which showed a reduction in the degree of pain post-surgery.
Quantifying the psychological outcomes will most certainly reduce risks as it will enable for
timely recognition of mental problems that could develop post-operatively. Early detection
and treatment will therefore allow for a quicker recovery, which will also maintain patient
motivation in complying with the post-op multidisciplinary therapy.
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1.5.6. Miscellaneous risks
1.5.6.1. Blood loss
Significant intraoperative blood loss was a complication that was initially overlooked in 2006
[16]; however, it was a concern amongst the initial transplants [2, 3] conducted and the
associated indirect risks posed from subsequent transfusions. However, as surgical techniques
have become more refined, the incidence of significant intraoperative blood loss has been
reduced.
1.5.6.2. Chronic renal insufficiency
This has so far developed in two patients subsequent to immunosuppressive therapy [4, 39].
Such problems had been predicted [26] in relation to long-term immunosuppression; however,
the incidence has so far been low [43]. Unless tolerance regimes become developed, the risk of
this complication will persist.
1.5.6.3. Malignancy
Neoplasia has been evidenced in three cases so far with one patient sustaining mortality
subsequent to a squamous cell carcinoma of the tongue [43]. This was due to the effects of
immunomodulation from an underlying HIV infection in the recipient. Another patient
developed a monoclonal B-cell lymphoma at 4 months [43] due to Epstein-Barr virus mismatch
implicating that stricter viral screening measures of donors need to be adapted. Cervical
dysplasia has also been reported in the first partial facial allograft in France for which the
patient underwent hysterectomy [47].
1.6. Conclusion
In conclusion, we can see that acute rejections have shown to affect almost all patients.
Although they have been well controlled with no graft loss, it should still draw focus towards
more research in this field and how to limit its incidence as there has been a report of one case
that has progressed towards chronic rejection impairing graft function. Infective complications
have affected 11 patients. Almost half of these could have been avoided if stricter protocols
were practised in terms of pre-operative viral screening of donor grafts. Six cases of cytome‐
galovirus and one case of EBV were acquired. These could have been prevented. Significant
complications can arise as a result of infections as was evidenced in the case of Epstein-Barr
virus acquisition from a donor graft causing monoclonal B-cell lymphoma. The risk of
unpredictability in functional improvement has certainly been disproved. All reported cases
so far excluding the three mortalities have demonstrated improved facial function to some
degree apart from one case of reduced graft function due to chronic rejection. Psychological
complications have been negligible apart from one case in China not complying to his
immunosuppressive therapy. This can be avoided by better patient selection and a more
thorough psychological assessment in terms of choosing transplant recipients. Also, it is
important to quantify the psychological outcome as it will help to improve the post-op follow-
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up and recognize mental problems that may develop. Concomitant limb and facial transplants
should be avoided as it has shown to increase mortality and morbidity in the two cases where
it has been attempted. Recipient co-morbidity status should therefore be considered pre-
operatively as it can increase the complication incidence. This has been further highlighted by
mortality in relation to one recipient with HIV succumbing to a malignant complication of the
tongue again emphasizing the importance of considering co-morbid state.
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